{"id":"W3135213711","doi":"10.1016/j.ccell.2021.02.013","title":"Progressive immune dysfunction with advancing disease stage in renal cell carcinoma","year":2021,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":517,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; National Human Genome Research Institute; Genentech; EMD Serono; Fondation de France; Eisai; Parker Institute for Cancer Immunotherapy; Danmarks Frie Forskningsfond; Kay Kendall Leukaemia Fund; Celldex Therapeutics; National Institutes of Health; BioMarin Pharmaceutical; Harvard Medical School; National Cancer Institute; Chinook Therapeutics; Gilead Sciences; G. Harold and Leila Y. Mathers Foundation; Dermatology Foundation; Leukemia and Lymphoma Society; Novartis; Bristol-Myers Squibb; Dana-Farber/Harvard Cancer Center; Merck; GlaxoSmithKline; Dana-Farber Cancer Institute; Roche; Astellas Pharma US; Pfizer; U.S. Department of Defense; Eli Lilly and Company; AstraZeneca; American Association for Cancer Research; Conquer Cancer Foundation; Exelixis","keywords":"Immune system; Immunotherapy; Cancer research; Tumor microenvironment; Clear cell renal cell carcinoma; CD8; Renal cell carcinoma; Biology; T cell; Myeloid; Cytotoxic T cell; Cell; Immunology; Cancer; Medicine; Internal medicine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008063668867447894,"score_gpt":0.245670689036705,"score_spread":0.2376070201692571,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}